AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Right on the heels of their $90M funding round, this week’s Pathfinder spotlights Varda and its cofounders, Will Bruey (CEO) and Delian Asparouhov (President). The LA-based startup harnesses microgravity for pharmaceutical development and manufacturing. In its latest mission, the company successfully processed ritonavir, a crucial antiviral drug utilized in HIV/AIDS treatment.
In addition to Varda’s origin story and the Series B fundraise, Mo, Will, and Delian discuss:
And much more…
This episode is brought to you by the Italian Trade Agency (ITA).
• Chapters •
00:00 Intro & ITA Ad
01:21 Varda’s origin
05:40 What are you building?
08:17 What does space have to offer for manufacturing?
12:00 The business case for space manufacturing
18:02 What drugs have been improved in space?
19:13 What happened to ZBLAN?
20:54 R&D for manufacturing in space
22:34 The W-1 mission
29:05 Customer traction
30:38 Where does Varda's business risk lie?
38:22 Competitive landscape
39:49 Potential partnerships
42:48 Regulatory learnings
45:30 The Series B
46:57 Use cases beyond pharma
48:19 Space stations
55:35 Other companies Will is excited about
57:22 Where would Delian invest his last space investment?
• Show notes •
Varda’s website — https://www.varda.com/
The Return of Ritonavir Paper: https://www.varda.com/papers/1711063046-return-of-the-ritonavir-a-study-on-the-stability-of-pharmaceuticals-processed-in-orbit-and-returned-to-earth.pdf
Will’s socials — https://twitter.com/WillBruey
Delian’s socials — https://twitter.com/zebulgar
Mo's socials — https://twitter.com/itsmoislam
Payload’s socials — https://twitter.com/payloadspace / https://www.linkedin.com/company/payloadspace
Pathfinder archive — Watch: https://www.youtube.com/@payloadspace
Pathfinder archive — Listen: https://pod.payloadspace.com/episodes
• About us •
Pathfinder is brought to you by Payload, a modern space media brand built from the ground up for a new age of space exploration and commercialization. We deliver need-to-know news and insights daily to 19,000+ commercial, civil, and military space leaders. Payload is read by decision-makers at every leading new space company, along with c-suite leaders at all of the aerospace & defense primes. We’re also read on Capitol Hill, in the Pentagon, and at space agencies around the world.
Payload began as a weekly email sent to a few friends and coworkers. Today, we’re a team distributed across four time zones and two continents, publishing five media properties across multiple platforms:
1) Payload, our flagship daily newsletter, sends M-F @ 9am Eastern
2) Pathfinder publishes weekly on Tuesday mornings (pod.payloadspace.com)
3) Polaris, our weekly policy briefing, publishes weekly on Tuesdays
4) Payload Research, our weekly research and analysis piece, comes out on Wednesdays
You can sign up for all of our publications here: https://payloadspace.com/subscribe/